Novel treatment options in lymphoma and leukemia 1

Reddy, Nishitha M.

We noted you are experiencing viewing problems

Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at support@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems.
No luck yet? More tips for troubleshooting viewing issues
Contact HST Support support@hstalks.com

Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
For additional help, please don't hesitate to contact HST support support@hstalks.com

We hope you have enjoyed this limited-length demo talk

Request free trial
Recommend to your librarian

Share
Share This Lecture
Email

Outlook

Email

Gmail

Live Mail

Yahoo!
Social

Facebook

Twitter

LinkedIn

Google+

VKontakte
Permalink
Replay Talk
Watch Part 2 of 2

This is a limited length demo talk; you may login or review methods of obtaining more access.

Slide Index
Topics Covered
Links
Citation & Info

Navigable Slide Index

Introduction
Timeline of new therapies approved for lymphoma
Examples of drugs in development for lymphoma
Novel agents in acute myeloid leukemia
Novel agents in lymphoma
Type II monoclonal antibodies (mab's)
GADOLIN study (design)
GADOLIN study (results)
GALLIUM study
Antibody-drug conjugates for cancer therapy
Brentuximab vedotin: antibody drug conjugate
Hodgkin lymphoma
Phase II study of brentuximab vedotin
5-year survival & durability of brentuximab vedotin
Response in relapsed T cell lymphomas
Brentuximab: mycosis fungoids, Sezary syndrome
Bortezomib: proteasome inhibition
Multicenter phase II study of bortezomib
Bortezomib-based therapy
HDAC inhibitors in PTCL/CTCL
Belinostat in patients with R/R PTCL: BELIEF trial
Phase II results of HDAC inhibitors in R/R PTCL

Topics Covered

Lymphoma and leukemia
Treatment of non-Hodgkin & Hodgkin lymphoma
Novel targeted agents in B and T-cell lymphoma (antibody–drug conjugates)

Links

Series:

Cancer Therapies in the Personalized Medicine Era

Categories:

Therapeutic Areas:

Talk Citation

Reddy, N.M. (2017), "Novel treatment options in lymphoma and leukemia 1", in The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at https://hstalks.com/bs/3515/)